A traditional Chinese medicine versus Western combination therapy in the treatment of rheumatoid arthritis: two-stage study protocol for a randomized controlled trial

Chi Zhang, Miao Jiang, Aiping Lu, Chi Zhang, Miao Jiang, Aiping Lu

Abstract

Background: The common randomized controlled trial design has distinct limitations when applied to Chinese medicine, because Chinese medicine identifies and treats 'Chinese medicine patterns' rather than diagnosed diseases. Chinese medicine patterns are a group of associated symptoms, tongue appearances and pulse characteristics. These limitations could be overcome by developing new strategies to evaluate the effect of Chinese medicine. The idea behind pattern-based efficacy evaluations may optimize clinical trial design by identifying the responsiveness-related Chinese medicine patterns.

Methods/design: This is a two-stage multi-center trial of Chinese herbal medicine for the management of rheumatoid arthritis. The stage one trial is an open-label trial and aims to explore what groups of Chinese medicine information (such as symptoms) correlates with better efficacy, and the stage two trial is a randomized, controlled, double-blind, double-dummy clinical trial that incorporates the efficacy-related information identified in the stage-one trial into the inclusion criteria.

Discussion: The indication of a Chinese herbal formula is a specific Chinese medicine pattern and not a single disease and stratifying a disease into several patterns with a group of symptoms is a feasible procedure in clinical trials. This study is the first to investigate whether this approach in the design of Chinese herbal medicine trials can improve responses.

Trial registration: ChiCTR-TRC-10000989.

Figures

Figure 1
Figure 1
The flowchart of the two-stage trial design.

References

    1. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468. doi: 10.1038/nature02626.
    1. Qiu J. Traditional medicine: A culture in the balance. Nature. 2007;448:126–127. doi: 10.1038/448126a.
    1. Angell M, Kassirer JP. Alternative medicine--the risks of untested and unregulated remedies. N Engl J Medm. 1998;339:839–841. doi: 10.1056/NEJM199809173391210.
    1. Tsang IK. Establishing the efficacy of traditional Chinese medicine. Nature Clinical Practice Rheumatology. 2007;3:60–61.
    1. WHO Traditional Medicine Strategy 2002-2005.
    1. Young Allan. The Creation of Medical Knowledge: Some Problems in Interpretation. Social Science & Medicine. 1996;15B:379–386.
    1. Flaws B. The Treatment of Modern Western Diseases with Chinese Medicine. Boulder: Blue Poppy Press; 2005.
    1. Jian Yan, Engle Veronica F, Yuxin He, Yan Jiao, Weikuan Gu. Study designs of randomized controlled trials not based on Chinese medicine theory are improper. Chinese medicine. 2009;4:3. doi: 10.1186/1749-8546-4-3.
    1. Aiping Lu, Xuewen Liu, Xiaorong Ding. Methodology of pharmacodynamic evaluation on Chinese herbal medicine based on syndrome differentiation. Journal of Chinese Integrative Medicine. 2009;7:501–504. doi: 10.3736/jcim20090601.
    1. Qinglin Zha, Yiting He, Xiaorong Ding, Miao Jiang, Xuewen Liu, Cheng Lu, Ian Tsang, Aiping Lu. The Predictive Role of Symptoms/signs on ACR20 Responses in Rheumatoid Arthritis Analyzed with Data Mining Approaches. BMEI. 2009. pp. 1–8.
    1. Li S, Hu X, Jing Z. Therapeutic effect of Yi Shen Juan Bi pill on Rheumatoid Arthritis. Zhejiang Clin Med J. 2008;10:628–629.
    1. Perera PK, Li Y, Peng C, Fang W, Han C. Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in adjuvant arthritis. Indian J Pharmacol. 2010;2:5–9.
    1. Perera PK, Peng C, Xue L, Li Y, Han C. Ex vivo and in vivo effect of Chinese herbal pill Yi Shen Juan Bi (YJB) on experimental arthritis. J Ethnopharmacol. 2011;134:171–175. doi: 10.1016/j.jep.2010.11.065.
    1. Pathirage-Kamal PERERA, Cheng PENG, Xue LV, Yun-Man LI, Wei-Rong FANG, Cai-Feng HAN. Effects of Yishen Juanbi (YJB) Pill on Experimental Rheumatoid Arthritis. Chinese Journal of Natural Medicines. 2010;8:57–61. doi: 10.3724/SP.J.1009.2010.00057.
    1. Jiang Q, Cao W, Tang XP. Tripterygium wilfordii Extract for Treating Rheumatoid Arthritis: Systematic Review. Zhongguo Zhong Yao Za Zhi. 2009;34:2637–2643.
    1. Tao XL, Dong Y, Zhang NZ. A double-blind study of T2 (tablets of polyglycosides of Tripterygium wilfordii Hook) in the treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 1987;26:399–402.
    1. James Dale, Nicola Alcorn, Hilary Capell, Rajan Madhok. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nature clinical practice rheumatology. 2007;3:450–458.
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324. doi: 10.1002/art.1780310302.
    1. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498–502. doi: 10.1002/art.1780350502.
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735. doi: 10.1002/art.1780380602.
    1. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ) Clin Exp Rheumatol. 2005;23:S14–S18.
    1. ICH Good Clinical Practices.
    1. Chen X, Wu T, Liu G. Chinese medicinal herbs for influenza: a systematic review. J Altern Complement Med. 2006;12:171–180. doi: 10.1089/acm.2006.12.171.
    1. Zhang MM, Liu XM, He L. Effect of integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence. World J Gastroenterol. 2004;10:3500–3505.
    1. He Y, Lu A, Zha Q, Yan X, Song Y, Zeng S, Liu W, Zhu W, Su L, Feng X, Qian X, Lu C. Correlations between symptoms as assessed in traditional Chinese medicine (TCM) and ACR20 efficacy response. A study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. J Clin Rheumatol. 2007;13:317–321. doi: 10.1097/RHU.0b013e31815d019b.
    1. Lu A, Chen KJ. Integrative medicine in clinical practice: from pattern differentiation in traditional Chinese medicine to disease treatment. Chin J Integr Med. 2009;15:152. doi: 10.1007/s11655-009-0152-6.
    1. He Y, Lu A, Zha Y, Tsang I. Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients. Complement Ther Med. 2008;16:206–211. doi: 10.1016/j.ctim.2007.08.005.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever